Outlook Therapeutics (NASDAQ:OTLK – Get Rating) posted its quarterly earnings results on Friday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), MarketWatch Earnings reports.
Outlook Therapeutics stock opened at $1.60 on Friday. Outlook Therapeutics has a one year low of $1.19 and a one year high of $3.27. The business has a fifty day moving average price of $1.78 and a 200-day moving average price of $1.61. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.20.
In other Outlook Therapeutics news, Director Kurt J. Hilzinger acquired 95,597 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The stock was bought at an average price of $1.49 per share, with a total value of $142,439.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt J. Hilzinger acquired 41,160 shares of the company’s stock in a transaction that occurred on Thursday, February 24th. The shares were acquired at an average cost of $1.46 per share, with a total value of $60,093.60. The disclosure for this purchase can be found here. Insiders bought 142,757 shares of company stock valued at $212,133 over the last ninety days. Corporate insiders own 2.30% of the company’s stock.
Outlook Therapeutics Company Profile (Get Rating)
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
- Get a free copy of the StockNews.com research report on Outlook Therapeutics (OTLK)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.